16 August 2024 — AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been approved in the US for the treatment of adult patients with resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC) and no known…Original Article
Imfinzi Approved in the US for the Treatment of Resectable Non-Small Cell Lung Cancer Before and After Surgery
